New antibiotic has been approved for uncomplicated UTIs; Cabometyx approved for advanced neuroendocrine tumors; new rosacea treatment option; Tremfya ...
The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from ...
Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are excellent examples along ...
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
Health and Me on MSN4d
FDA Approves Tremfya For Active Crohn's DiseaseCrohn's disease is a type of inflammatory bowel disease (IBD) that causes swelling and irritation of the tissues, called ...
HealthDay on MSN4d
FDA Approves Tremfya for Active Crohn Disease in AdultsThe U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback